At US$6.57, Is Ultralife Corporation (NASDAQ:ULBI) Worth Looking At Closely?

At US$6.57, Is Ultralife Corporation (NASDAQ:ULBI) Worth Looking At Closely?

While Ultralife Corporation (NASDAQ:ULBI) might not have the largest market cap around , it saw significant share price movement during recent months on the NASDAQGM, rising to highs of US$11.37 and falling to the lows of US$6.52. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Ultralife's current trading price of US$6.57 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Ultralife's outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest analysis for Ultralife

What's The Opportunity In Ultralife?

Ultralife appears to be expensive according to our price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average. In this instance, we've used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock's cash flows. We find that Ultralife's ratio of 26.18x is above its peer average of 19.66x, which suggests the stock is trading at a higher price compared to the Electrical industry. If you like the stock, you may want to keep an eye out for a potential price decline in the future. Given that Ultralife's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

What kind of growth will Ultralife generate?

earnings-and-revenue-growth
NasdaqGM:ULBI Earnings and Revenue Growth January 5th 2024

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. In Ultralife's case, its earnings over the next year are expected to double, indicating an incredibly optimistic future ahead. This should lead to stronger cash flows, feeding into a higher share value.

What This Means For You

Are you a shareholder? It seems like the market has well and truly priced in ULBI's positive outlook, with shares trading above industry price multiples. At this current price, shareholders may be asking a different question – should I sell? If you believe ULBI should trade below its current price, selling high and buying it back up again when its price falls towards the industry PE ratio can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.